Mobia Medical (MOBI) Q3 2026 earnings review
Mobia Medical raises its sales plan, but losses still widen
Mobia Medical, the maker of the Vivistim nerve-stimulation implant for stroke survivors, grew fast by putting more sales reps into the field while losses stayed heavy. Revenue rose 73% from a year ago to $15.6 million, above what the company's own prior plan pointed to, and chief executive Richard Foust raised the full-year outlook. However, by our math the new target leaves fourth-quarter sales growing about 50% from a year ago and barely rising from the third quarter.
| Revenue | $15.6M +73% from a year ago |
|---|---|
| Average active sales territories | 40 35.5 last quarter and 22.5 a year ago |
| Gross margin | 83.2% +3.6 percentage points from a year ago |
| Full-year 2026 revenue outlook | Raised $2.25M middle of the range: $57.25M (+78.5%) |
⚖️ Verdict: 🟢 Bullish
The story got better because Mobia beat its initial second-half pace and won endorsement in the American Heart Association's 2026 stroke guidelines, which should help its push for private insurance coverage. One caution: beating the third-quarter pace implied by the old plan shows that management set its first public target cautiously, not that sales per territory are accelerating. Revenue per active territory slipped slightly from a year ago by our math, and quarterly cash burn stayed above $16 million.
The question now is whether the fourth-quarter slowdown implied by the outlook is another cautious target or a sign that newly hired territories take longer to ramp. If management is simply conservative, fourth-quarter sales should grow in step with the 4.5 territories added this quarter; if new territories start slowly, revenue per territory will dip. Fourth-quarter results and the November 2026 Medicare hospital payment rule will settle both debates.
🐂 Bull Case
Sales Team Expansion Drives the Higher Outlook
Mobia Medical sells Vivistim, an implanted nerve-stimulation device that helps stroke survivors regain arm and hand movement. Because the device requires surgeon training and therapy coordination, the Austin company grows by hiring territory managers and waiting nine months for them to become active.
Average active territories reached 40 this quarter, up from 35.5 in the second quarter and 22.5 a year ago. That 4.5-territory addition matched the pace management discussed three months ago and lifted revenue 73% to $15.6 million. By our math, sales beat the $14.7 million quarterly pace implied by the old full-year plan, and chief executive Richard Foust raised the 2026 outlook by $2.25 million at the middle of the range.
What to watch: fourth-quarter active territory additions on the conference call. Adding another four to five territories will show the hiring pipeline can support 2027 growth.
Heart Association Adds Vivistim to Stroke Guidelines
Private insurers have been slow to cover Vivistim automatically, forcing hospitals and doctors to seek approval for each patient one by one. Mobia has been publishing clinical studies to prove the therapy works over the long term and win broader insurance coverage.
In the third quarter, the American Heart Association (AHA) added paired vagus nerve stimulation (VNS), the therapy Vivistim delivers, to its updated 2026 stroke recovery guidelines. Foust called the move "validation of our evidence-based approach to stroke recovery". Guideline inclusion matters because private health plans often require endorsement from major medical societies before writing standard coverage policies.
What to watch: formal coverage policy updates from major commercial insurers in 2027. Converting the AHA endorsement into written payer policies would remove the case-by-case approval bottleneck.
Lower Freight and Tariff Costs Lifted Gross Margin
Mobia makes its devices through a contract manufacturer in Uruguay, exposing its cost of goods sold (the direct cost of making and shipping the implants) to shipping and trade charges. Last quarter, the filing left unclear whether freight and tariffs were helping or hurting margins.
This quarter's release settled the question: gross margin rose 3.6 percentage points from a year ago to 83.2%, and cost of goods sold fell from 20.4% of revenue to 16.8%. The medical device maker said the gain came "primarily due to lower freight and tariff costs as a percentage of revenue and lower inventory write-offs compared to the prior year period".
What to watch: full-year gross margin in the fourth-quarter report. Holding the margin above 83% will confirm that shipping and inventory losses stay small as unit volume grows.
🐻 Bear Case
Revenue Growth Follows Hiring Rather Than Higher Output
"This quarter, we delivered our strongest results yet. Revenue growth of 73% reflects the strength of our commercial execution and the predictable nature of our patient funnel," Foust said. The numbers show that growth still comes from adding sales territories rather than getting more revenue out of existing ones.
- Average active territories: 40, up 78% from 22.5 a year ago
- Revenue per active territory: about $390,000 by our math, down 2.5% from about $401,000 a year ago
- Fourth-quarter revenue growth implied by the new outlook: about 50% from a year ago by our math, down from 73% in Q3 and 102% in Q2
Beating the third-quarter pace implied by the old plan shows that management set its first public target cautiously. However, because revenue per territory stays near $390,000 and Mobia adds a steady four to five territories a quarter, percentage growth slows as the base gets larger.
What to watch: revenue per active territory in the fourth quarter. A reading above $400,000 is needed to show that mature territories can grow faster than the hiring rate.
Cash Burn Holds Near $16 Million a Quarter
Mobia raised $134 million in its May 2026 initial public offering to fund its commercial buildout, and spending is rising almost as fast as sales. Operating expenses grew 71% from a year ago to $31.5 million on what the company called "continued investment in the Company’s commercial organization to support revenue growth".
Selling, general and administrative costs (sales salaries, commissions and overhead) reached $29.0 million, or 185.6% of revenue, down 1.1 percentage points from 186.7% a year ago. Research and development fell 1.5 percentage points to 16.3% of sales, but the operating loss still widened from $11.3 million to $18.5 million, and cash fell by $16.4 million in the quarter to $160.7 million.
What to watch: quarterly operating loss and cash balance in the fourth-quarter report. Unless operating losses stop widening as revenue scales, Mobia will keep burning over $60 million a year.
Risks this quarter didn't answer
Several standing reimbursement, balance-sheet and operational risks received no update or full breakdown in the third-quarter earnings release.
- Medicare 2027 hospital payment rule: Medicare currently pays hospitals about $45,000 for the Vivistim procedure under a temporary new-technology category; the final 2027 rule is due in November 2026 and was not mentioned in the release.
- Rising warranty reserves: product warranty liability on the balance sheet rose 24.5% from last quarter to $1.57 million, outpacing the 15.6% sequential rise in revenue; the quarterly filing will show actual device replacement claims.
- Single-factory dependence: Mobia relies on one contract facility in Uruguay for device assembly, leaving supply and tariff exposure unchanged.
💲 Other KPIs
Both working-capital lines grew faster than sales this quarter. Inventory rose 20.2% from the second quarter to $8.35 million, and accounts receivable (uncollected customer bills) rose 23.7% to $7.01 million, compared with 15.6% sequential revenue growth. The buildup tied up cash as the company stocked devices for new territories.
Net loss per share narrowed from -$13.31 a year ago and -$1.10 in the second quarter, even though total net loss widened 51.8% from last year to $17.3 million. The per-share drop reflects the May 2026 initial public offering and preferred-stock conversion, which lifted weighted-average shares to 33.3 million from 0.86 million a year ago.
🔮 Guidance
Raised. Management lifted the full-year sales plan by $2.25 million at the middle of the range, calling for 78% to 79% growth over 2025. By our math, after $41.2 million in the first nine months, the outlook leaves $15.8 million to $16.3 million for the fourth quarter—up just 3% sequentially at the middle of the range, with year-over-year growth slowing to about 50% against a tougher fourth-quarter comparison.
❓ Key Questions
Did Medicare keep the $45,000 hospital payment for 2027?
Medicare's final 2027 hospital outpatient payment rule is due in November 2026. Investors need to know if Vivistim kept its temporary new-technology payment rate of about $45,000, because a cut would hurt hospital economics in 2027.
Why does the outlook imply almost flat fourth-quarter sales?
By our math, the raised full-year outlook leaves $16.1 million at the middle of the range for Q4, up less than $0.5 million from Q3 despite adding 4.5 active territories. Management has not said whether it expects lower holiday procedure volume or lower output from new reps.
How many implant units did Mobia sell in Q3?
On last quarter's call, management disclosed selling about 367 implant units in Q2. The Q3 release states unit sales rose but gives no number, leaving investors unable to separate unit volume from average selling prices.
Why did warranty reserves rise faster than sales again?
Product warranty liability on the balance sheet climbed 24.5% sequentially to $1.57 million and is up 86% since December, outpacing revenue. Management has not explained whether device replacement rates are rising.